Burns – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Burns – Pipeline Review, H1 2017’, provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Burns

The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Burns therapeutics and enlists all their major and minor projects

The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Burns

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Burns

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

American Gene Technologies International Inc

Biogenomics Ltd

CytoTools AG

Destiny Pharma Ltd

GangaGen Inc

Lakewood-Amedex Inc

Madam Therapeutics BV

Mallinckrodt Plc

MediWound Ltd

Mitochon Pharmaceuticals Inc

Phosphagenics Ltd

Se-cure Pharmaceuticals Ltd

USV Pvt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burns - Overview

Burns - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burns - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burns - Companies Involved in Therapeutics Development

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

American Gene Technologies International Inc

Biogenomics Ltd

CytoTools AG

Destiny Pharma Ltd

GangaGen Inc

Lakewood-Amedex Inc

Madam Therapeutics BV

Mallinckrodt Plc

MediWound Ltd

Mitochon Pharmaceuticals Inc

Phosphagenics Ltd

Se-cure Pharmaceuticals Ltd

USV Pvt Ltd

Burns - Drug Profiles

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-3APO - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

albumin (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLO-ASC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AyuV-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bromelains - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epidermal growth factor biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMSP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neu-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligomer G for Burn Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XF-70 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Featured News & Press Releases

Mar 03, 2017: Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid in Burn Management Published in BioMed Research International

Feb 09, 2017: Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area

Feb 06, 2017: MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid Expanding Treatment of Severe Burns to Children Age One to Four

Aug 24, 2016: MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2016

Aug 08, 2016: Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns

Jun 07, 2016: MediWound’s NexoBrid Receives Reimbursement in Italy

May 19, 2016: MediWound’s NexoBrid Highlighted in “Best Oral Presentation” at the British Burn Association 49th Annual Conference and Scientific Meeting

May 02, 2016: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting

Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized

Feb 22, 2016: Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program

Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)

Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters

Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania

Oct 31, 2015: Anterogen: Phase II IND Approval for "ALLO-ASC-BI"

Oct 26, 2015: Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Burns, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Burns – Pipeline by AlgiPharma AS, H1 2017

Burns – Pipeline by Alliance Pharma Plc, H1 2017

Burns – Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Burns – Pipeline by American Gene Technologies International Inc, H1 2017

Burns – Pipeline by Biogenomics Ltd, H1 2017

Burns – Pipeline by CytoTools AG, H1 2017

Burns – Pipeline by Destiny Pharma Ltd, H1 2017

Burns – Pipeline by GangaGen Inc, H1 2017

Burns – Pipeline by Lakewood-Amedex Inc, H1 2017

Burns – Pipeline by Madam Therapeutics BV, H1 2017

Burns – Pipeline by Mallinckrodt Plc, H1 2017

Burns – Pipeline by MediWound Ltd, H1 2017

Burns – Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Burns – Pipeline by Phosphagenics Ltd, H1 2017

Burns – Pipeline by Se-cure Pharmaceuticals Ltd, H1 2017

Burns – Pipeline by USV Pvt Ltd, H1 2017

Burns – Dormant Projects, H1 2017

Burns – Dormant Projects, H1 2017 (Contd..1), H1 2017

Burns – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Burns, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports